Surrogate endpoints are a common application of biomarkers to estimate clinical benefit in clinical trials, despite questions about reliability. This article discusses ongoing opportunities for their validation, in the context of a regulatory environment in which they are increasingly championed.
Get full access to this article
View all access options for this article.
References
1.
V.Prasad, C.Kim, M.Burotto, and A.Vandross, “The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-Analyses,”JAMA Internal Medicine175, no. 8 (2015): 1389-1398, doi: 10.1001/jamainternmed.2015.2829.
2.
J. S.Yudkin, K. J.Lipska, and V. M.Montori, “The Idolatry of the Surrogate,”BMJ343 (2011): D7995, doi: 10.1136/bmj.d7995; R.Rodriguez-Gutierrez and R. G.McCoy, “Measuring What Matters in Diabetes,”JAMA321, no. 19 (2019): 1865-1866, doi: 10.1001/jama.2019.4310.
3.
N. S.Downing, J. A.Aminawung, N. D.Shah, H. M.Krumholz, and J. S.Ross, “Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012,”JAMA311, no. 4 (2014): 368–377, doi: 10.1001/jama.2013.282034.
J. A.Beaver, L. J.Howie, L.Pelosof, et al., “A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review,”JAMA Oncology4, no. 6 (2018): 849-856, doi: 10.1001/jamaoncol.2017.5618.
6.
A. M.Pease, H.M.KrumholzN. S.Downing, J. A.Aminawung, N. D.Shah, and J. S.Ross, “Postapproval Studies of Drugs Initially Approved by the FDA on the Basis of Limited Evidence: Systematic Review,”BMJ357 (2017): j1680, doi: 10.1136/bmj.j1680.
7.
J. D.Wallach, J. S.Ross, and H.Naci, “The US Food and Drug Administration's Expedited Approval Programs: Evidentiary Standards, Regulatory Trade-Offs, and Potential Improvements,”Clinical Trials15, no. 3 (2018): 219-229, doi: 10.1177/1740774518770648; J. D.Wallach, A. C.Egilman, S. S.Dhruva, et al., “Postmarket Studies Required by the US Food and Drug Administration for New Drugs and Biologics Approved Between 2009 and 2012: Cross Sectional Analysis,”BMJ361 (2018): k2031, doi: 10.1136/bmj.k2031.
8.
B. L.Strom, M.Buyse, J.Hughes, and B. M.Knoppers, “Data Sharing, Year 1 — Access to Data from Industry-Sponsored Clinical Trials,”New England Journal of Medicine371, no. 22 (2014): 2052-2054, doi: 10.1056/NEJMp1411794.
9.
J. S.Ross, J.Waldstreicher, S.Bamford, et al., “Overview and Experience of the YODA Project with Clinical Trial Data Sharing After 5 Years,”Scientific Data5 (2018): 180268, doi: 10.1038/sdata.2018.268.
